ChemBriefASP Isotopes Inc. Balance Sheet Overview
ASP Isotopes Inc. presented its annual balance sheet data from 2022 to 2025, showing significant growth in total assets and equity.
Yahoo Finance UK · 2026-10-31 08:28 UTC
ASP Isotopes Inc. presented its annual balance sheet data from 2022 to 2025, showing significant growth in total assets and equity.
ASP Isotopes Inc. stock displays seasonal return trends from 2022 to 2026, priced at $2.02 on October 30 with minor after-hours recovery.
ASP Isotopes Inc. targets $300 million EBITDA by 2031 via isotope shipments, helium scale-up, and radiopharmacy acquisitions. The firm also pursues a VHH cancer-treatment pipeline within its expansion
At the Emerging Growth Conference 97, ASP Isotopes detailed its commercial growth strategy in helium, nuclear medicine, and semiconductor materials. Leveraging $250 million in cash, the company aims f
ASP Isotopes' subsidiary Renergen achieved stable liquid helium production at its Free State project, storing output for initial customer deliveries ahead of commercial launch. The company continues a
ASP Isotopes Inc. announced its subsidiary Tetra4 has begun stable liquid helium production at its Virginia Gas Project in South Africa. Full nameplate capacity is expected by Q4 2026, supporting exis
ASP Isotopes announced stable liquid helium production at its Renergen Virginia Gas Project in South Africa, targeting 70,000 cubic feet daily with full capacity expected by Q4 2026.
ASP Isotopes Inc filed a Form 8K with the SEC on October 26, signaling potential material events, though the announcement lacked specific operational details.
ASP Isotopes Inc.'s subsidiary Renergen Limited has achieved stable liquid helium production at its Virginia Gas Project in South Africa. The project targets 70 Mcf/day of liquid helium by Q4 2026 to
ASP Isotopes Inc. reported a Form 4 insider transaction filed by CFO Heather Kiessling on October 21.
ASP Isotopes Inc subsidiary Quantum Leap Energy and South African state-owned Necsa formed a joint venture to produce high-assay low-enriched uranium (HALEU) at Pelindaba, securing an off-take agreeme
ASP Isotopes COO Robert Ainscow sold 22,500 shares on Oct 14, 2026, via a 10b5-1 plan for taxes, retaining 2.2M shares.
ASP Isotopes' subsidiary Quantum Leap Energy partnered with South Africa's Necsa to develop a commercial HALEU production facility. QLE holds 80% ownership and has secured off-take agreements with Ter
ASP Isotopes' subsidiary Quantum Leap Energy signed a binding agreement with Necsa to form a joint venture for HALEU production, with QLE holding 80% ownership and supported by off-take agreements wit
ASP Isotopes' subsidiary Quantum Leap Energy formed a joint venture with Necsa to produce High-Assay Low-Enriched Uranium in South Africa, securing off-take agreements with TerraPower.
ASP Isotopes Inc. filed a Form 144 on October 14, indicating an insider's intent to sell restricted stock, according to Investing.com.
ASP Isotopes Inc. disclosed a 15.1% beneficial ownership stake in ENDRA Life Sciences Inc., comprising common shares and pre-funded warrants. A proposed merger with Noble Africa LLC may grant ASP Isot
ASP Isotopes Inc. filed a Form 8K on October 2nd, indicating a significant corporate event. Specific details of the disclosure require reviewing the official filing.
ENDRA Life Sciences filed a Form S-4 registration statement to merge with Noble Africa, a subsidiary of ASP Isotopes. The deal aims to combine ASP's South African assets with a Nasdaq-listed entity pe
ENDRA filed a Form S-4 registration statement for its proposed merger with Noble Africa, a subsidiary of ASP Isotopes, incorporating material disclosures regarding Renergen and financial impacts.
ASP Isotopes director Robert John Andrew Ryan purchased 15,000 shares at an average price of $2.68, raising his direct holdings to 675,222 shares. The acquisition occurred across multiple transactions
ASP Isotopes Inc. director Robert John Andrew Ryan purchased 8,000 shares at an average price of $2.70 per share. The transaction was reported via Form 4, signaling positive insider sentiment.
ASP Isotopes Inc. financial overview on the Hannover Stock Exchange shows a closed market with no trades, presenting an early-stage report structure without detailed revenue figures.
Halper Sadeh LLC is investigating ASP Isotopes Inc. officers for potential fiduciary breaches, offering free consultations to long-term shareholders seeking corporate governance reforms.
ASP Isotopes director Todd Wider filed notice to sell 200,000 shares worth $590,000 via J.P. Morgan, following two prior sales in June 2026.
At its inaugural Capital Markets Day, ASP Isotopes outlined a strategy targeting $300 million EBITDA by 2031 through nuclear medicine, helium, and LNG production, with commercial shipments commencing
ASP Isotopes targets $300 million EBITDA by 2031 following its inaugural Capital Markets Day, driven by liquid helium, radiopharmacy, and stable isotope commercialization. The company also announced p
ASP Isotopes Inc. COO Robert Ainscow sold 8,438 shares at $4.292 per share under a Rule 10b5-1 plan to cover tax withholding obligations on vested restricted stock awards.
ASP Isotopes Inc. is exploring a nuclear fuel conversion pilot in Namibia via subsidiary QLE to strengthen global fuel-cycle capabilities. The project leverages Namibia's uranium production to transit
ASP Isotopes Inc. submitted a filing under Securities Act Rule 425 concerning prospectuses and communications related to ongoing business combination transactions.
ASP Isotopes Inc. plans to commence commercial helium production and expand stable isotope facilities, including Silicon-28 and Carbon-14, within six months. Initial shipments from its South African p
ASP Isotopes' subsidiary Tetra4 has begun commissioning its Phase 1 liquid helium plant in South Africa, targeting first commercial shipments by September 2026. The project is projected to generate ov
ENDRA Life Sciences announced that ASP Isotopes' partner, Tetra4, has initiated commissioning for the liquid helium plant at the Virginia Gas Project. This marks a significant operational milestone fo
ASP Isotopes Inc.'s subsidiary Renergen has commenced commissioning a liquid helium plant in South Africa to address global shortages. Commercial shipments are anticipated by September 2026, with Phas
ASP Isotopes Inc. announced its subsidiary Quantum Leap Energy is evaluating metal conversion opportunities in Namibia. An environmental assessment is underway for a proposed pilot-scale hydrofluorina
ASP Isotopes Inc. submitted a Form 8K filing on August 18, leading to a 3.98% decline in its common stock price as reported by Investing.com.
ASP Isotopes reported a quarterly loss of $0.28 per share, missing analyst estimates by $0.11. Shares fell 0.2% to $4.27 following the release, while insiders sold over $2 million worth of stock.
ASP Isotopes Inc. reported quarterly revenue of $5.1 million and narrowed its net loss to $34.0 million following the acquisition of Renergen. The deal diversified the company into helium and LNG sect
ASP Isotopes secured a five-year take-or-pay LNG contract with a South African food processor for its Virginia Gas Project. The agreement covers 10% of Phase 1 capacity at over $16 per GJ, with produc
ASP Isotopes Inc. is set to release Q2 2026 earnings on August 14th, with analysts forecasting a $0.17 per share loss and $4.47 million revenue.
ASP Isotopes Inc. filed a Form 8K on August 6 according to Investing.com, though the announcement provided no further details regarding the specific contents of the filing.
ASP Isotopes Inc.'s subsidiary Tetra4 secured a five-year take-or-pay contract to supply LNG from South Africa's Virginia Gas Project to a food processor, covering 10% of Phase 1 capacity at over $16/
ASP Isotopes' subsidiary Tetra4 secured a five-year LNG supply contract to a domestic food processor via the Virginia Gas Project in South Africa, targeting commercial operations in Q3 2026 at over $1
ASP Isotopes will host investor meetings at the Citi Natural Resources Conference on August 13, 2026, discussing proposed merger transactions involving ENDRA, Renergen, and Noble Africa.
ASP Isotopes Inc. will host investor meetings at Citi's 2026 Natural Resources Conference, showcasing isotope enrichment technologies for critical materials and announcing a proposed merger with ENDRA
ASP Isotopes forecasts $14 million revenue for its PET Labs division by 2026, while helium production and isotope enrichment facilities near commercial launch. Subsidiary Renergen expects $27 million
ASP Isotopes reported over 50% organic revenue growth for its PET Labs segment in H1 2026, while isotope facilities and Renergen projects approach key milestones ahead of Q2 financial results.
ASP Isotopes reported 50% organic revenue growth in PET Labs and near-commercial production of Silicon-28 and Ytterbium-176. The company highlighted helium production plans amid global shortages while
ASP Isotopes Inc. will present at the Canaccord Genuity Growth Conference on August 12, 2026, led by CCO Viktor Petkov. The press release also highlighted proposed merger transactions with ENDRA, Rene
ASP Isotopes announced a live webcast of its Chief Commercial Officer's presentation at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The session will detail proprietary sepa